NCT06285370View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 29, 2023

Primary Completion Date

August 12, 2025

Study Completion Date

November 13, 2025

Conditions
Cutaneous T-Cell Lymphoma
Interventions
DRUG

Mogamulizumab

Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met.

Trial Locations (8)

100034

Peking University First Hospital, Department of Dermatology and Venereology, Beijing

110002

The First Hospital of China Medical University, Shenyang

310005

ZheJiang Cancer Hospital, Hangzhou

450052

First Affiliated Hospital of Zhengzhou University, Henan

510060

Sun Yat-sen University Cancer Center, Department of Medical Oncology, Guangzhou

610044

West China Hospital, Sichuan University, Chengdu

Unknown

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

010000

The Affiliated Hospital of Inner Mongolia Medical University, Hohhot

All Listed Sponsors
lead

Kyowa Kirin China Pharmaceutical Co., Ltd.

INDUSTRY